Wealth Enhancement Advisory Services LLC Cuts Stock Holdings in Celcuity, Inc. $CELC

Wealth Enhancement Advisory Services LLC reduced its stake in Celcuity, Inc. (NASDAQ:CELC) by 39.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,793 shares of the company’s stock after selling 10,476 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Celcuity were worth $777,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of CELC. Soleus Capital Management L.P. boosted its holdings in shares of Celcuity by 17.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after purchasing an additional 437,696 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Celcuity in the second quarter worth about $3,197,000. Ameriprise Financial Inc. lifted its position in shares of Celcuity by 27.6% in the second quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock worth $10,263,000 after buying an additional 166,324 shares in the last quarter. Eventide Asset Management LLC boosted its stake in Celcuity by 9.8% during the second quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after buying an additional 123,774 shares during the last quarter. Finally, Saturn V Capital Management LP grew its holdings in Celcuity by 8.4% during the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after buying an additional 91,843 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

CELC has been the topic of several recent research reports. Jefferies Financial Group upped their price objective on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Stifel Nicolaus boosted their price target on shares of Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wells Fargo & Company assumed coverage on shares of Celcuity in a research note on Friday, December 12th. They set an “overweight” rating and a $126.00 price target on the stock. Craig Hallum lifted their price objective on shares of Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $105.25.

Insider Transactions at Celcuity

In other news, Director David Dalvey sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the sale, the director directly owned 90,000 shares in the company, valued at approximately $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard E. Buller sold 3,000 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $105.69, for a total value of $317,070.00. Following the transaction, the director owned 6,760 shares of the company’s stock, valued at approximately $714,464.40. The trade was a 30.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 26,900 shares of company stock worth $3,094,917 over the last three months. 15.78% of the stock is currently owned by corporate insiders.

Celcuity Stock Down 0.3%

NASDAQ CELC opened at $111.00 on Wednesday. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The company has a fifty day moving average of $104.68 and a two-hundred day moving average of $73.93. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of -30.25 and a beta of 0.36. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.13. On average, analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.